Profile data is unavailable for this security.
About the company
Onconetix, Inc. is a commercial stage biotechnology company. It is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has Entadfi, a Food and Drug Administration approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a next generation protein-based blood test that can be done with the same sample as a patient’s regular PSA test. Proteomedix is seeking to develop diagnostic, prognostic, and predictive tools to enable cancer management at all stages of disease progression.
- Revenue in USD (TTM)1.46m
- Net income in USD-53.12m
- Incorporated2018
- Employees12.00
- LocationOnconetix Inc201 E. Fifth Street, Suite 1900CINCINNATI 45202United StatesUSA
- Phone+1 (513) 620-4101
- Fax+1 (845) 818-3588
- Websitehttps://onconetix.gcs-web.com/
Mergers & acquisitions
Acquired company | ONCO:NAQ since announced | Transaction value |
---|---|---|
ProteoMediX Ltd | -69.08% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Link Reservations Inc | 0.00 | -480.90k | 1.69m | 0.00 | -- | -- | -- | -- | -46.51 | -46.51 | 0.00 | -13.99 | 0.00 | -- | -- | -- | -246.84 | -- | -- | -- | -- | -- | -- | -- | -- | -2.43 | -- | -- | -- | -- | -22.69 | -- | -- | -- |
cbdMD Inc | 20.64m | -23.42m | 1.75m | 52.00 | -- | 0.5783 | -- | 0.0848 | -18.95 | -18.95 | 7.85 | 0.8055 | 0.8817 | 2.01 | 20.35 | 396,856.90 | -82.98 | -38.59 | -112.36 | -41.50 | 63.43 | 63.80 | -94.12 | -87.98 | 0.5172 | -3.89 | 0.3128 | -- | -31.77 | 120.91 | 63.64 | -- | -4.95 | -- |
Procyon Corp | 4.77m | -387.79k | 1.87m | 17.00 | -- | 0.8824 | -- | 0.3924 | -0.0478 | -0.0478 | 0.5891 | 0.2774 | 1.39 | 1.94 | 9.60 | 280,817.70 | -10.81 | 3.52 | -13.69 | 4.23 | 78.01 | 73.30 | -7.78 | 2.52 | 2.22 | -- | 0.00 | -- | -3.22 | 3.11 | 70.44 | -- | 30.98 | -- |
Psyence Biomedical Ltd | 0.00 | 1.52m | 2.00m | -- | -- | -- | 1.32 | -- | -0.0442 | -0.0442 | 0.00 | -0.3979 | 0.00 | -- | -- | -- | 1.13 | -- | 1.20 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.63 | -- | -- | -- |
InVitro International | 716.89k | 6.22k | 2.05m | 16.00 | 257.14 | 2.80 | -- | 2.86 | 0.0004 | 0.0004 | 0.0402 | 0.0321 | 1.15 | -- | -- | -- | 0.995 | 7.89 | 1.09 | 8.83 | -- | -- | 0.8676 | 5.90 | -- | -- | -- | -- | -5.11 | 1.33 | -87.77 | -16.14 | -- | -- |
SOHM Inc | -100.00bn | -100.00bn | 2.29m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Onconetix Inc | 1.46m | -53.12m | 2.45m | 12.00 | -- | -- | -- | 1.68 | -2.62 | -2.62 | 0.0723 | 1.27 | 0.0328 | 3.45 | 5.30 | 121,979.20 | -119.09 | -- | -215.11 | -- | -57.21 | -- | -3,629.24 | -- | 0.091 | -11.87 | 0.2984 | -- | -- | -- | -176.78 | -- | -- | -- |
Scorpius Holdings Inc | 9.85m | -29.57m | 2.52m | 82.00 | -- | 0.0155 | -- | 0.2555 | -183.17 | -200.56 | 53.89 | 51.92 | 0.1552 | -- | 11.08 | 120,061.60 | -49.90 | -39.37 | -59.65 | -43.18 | 64.27 | -- | -321.53 | -1,068.21 | 0.3127 | -43.94 | 0.3569 | -- | 1,789.58 | 3.84 | 1.96 | -- | 27.32 | -- |
Panacea Life Sciences Holdings Inc | 2.76m | -7.67m | 2.67m | 40.00 | -- | -- | -- | 0.9666 | -0.4554 | -0.4554 | 0.164 | -0.5255 | 0.1537 | 1.62 | 10.13 | 69,098.25 | -42.65 | -69.04 | -- | -225.03 | -139.49 | -181.62 | -277.51 | -505.41 | 0.0285 | -2.12 | 4.79 | -- | 46.59 | -- | 12.33 | -- | -- | -- |
Altamira Therapeutics Ltd | 186.11k | -2.09m | 2.68m | 10.00 | -- | -- | -- | 14.42 | -27.47 | -27.47 | 0.2205 | -0.0743 | 0.0407 | 1.00 | 2.96 | 18,610.75 | -45.74 | -68.57 | -- | -117.99 | -8.39 | -- | -1,124.78 | -26,516.34 | 1.79 | -12.18 | -- | -- | -- | -- | 90.46 | -- | -- | -- |
Scisparc Ltd | 0.00 | -6.96m | 2.73m | 3.00 | -- | 7.66 | -- | -- | -1.22 | -1.51 | 0.00 | 0.0344 | 0.00 | -- | -- | 0.00 | -92.51 | -69.39 | -152.41 | -111.07 | -- | -- | -- | -527.17 | -- | -- | 0.9371 | -- | 113.73 | -- | -97.61 | -- | -- | -- |
Aoxing Pharmaceutical Company Inc | 30.11m | -1.46m | 3.21m | 339.00 | -- | 0.0375 | -- | 0.1065 | -0.0192 | -0.0192 | 0.3951 | 0.2507 | 0.496 | 2.32 | 2.56 | -- | -2.41 | -14.54 | -7.06 | -35.45 | 76.19 | 68.51 | -4.85 | -37.69 | 0.7368 | 0.3387 | 0.6052 | -- | 26.88 | 37.20 | -62.49 | -- | -38.80 | -- |
Tonix Pharmaceuticals Holding Corp | 12.46m | -149.01m | 3.25m | 103.00 | -- | 0.0345 | -- | 0.2605 | -110.99 | -110.99 | 6.16 | 4.28 | 0.1083 | 0.8436 | -- | 120,951.50 | -129.55 | -59.46 | -157.22 | -65.92 | 21.59 | -- | -1,196.12 | -5,126.73 | 0.7181 | -- | 0.1678 | -- | -- | -- | 0.1874 | -- | 320.57 | -- |
Shuttle Pharmaceuticals Holdings Inc | 0.00 | -7.20m | 3.25m | 8.00 | -- | 0.4796 | -- | -- | -10.29 | -10.29 | 0.00 | 3.04 | 0.00 | -- | -- | 0.00 | -123.53 | -- | -147.27 | -- | -- | -- | -- | -- | -- | -4.32 | 0.5076 | -- | -- | -- | -112.71 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
American Money Management Corp.as of 30 Jun 2024 | 1.44m | 6.45% |
Cetera Investment Advisers LLCas of 31 Mar 2024 | 320.00k | 1.43% |
Z�rcher Kantonalbank (Investment Management)as of 30 Jun 2024 | 306.08k | 1.37% |
Bank of America, NA (Private Banking)as of 31 Mar 2024 | 125.00k | 0.56% |
Two Sigma Securities LLCas of 31 Mar 2024 | 113.43k | 0.51% |
Fifth Third Bank, NA (Investment Management)as of 30 Jun 2024 | 96.20k | 0.43% |
Geode Capital Management LLCas of 30 Jun 2024 | 95.26k | 0.43% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 73.51k | 0.33% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 53.56k | 0.24% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 38.29k | 0.17% |